ATLANTA--The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination, researchers from Dana-Farber Cancer Institute in Boston will report at the American Society of Clinical Oncology's annual meeting in Atlanta.

The survival advantage emerged from an international clinical trial of more than 500 patients with squamous cell carcinoma of the head and neck treated with a sequential regimen that included induction chemotherapy and chemoradiotherapy, explains Marshall R. Posner, MD, director of head and neck oncology at Dana-Farber.

"This changes the standard of care for chemotherapy and radiation for head and neck cancer in this country," says Posner, who will present the data at a scientific special session on head and neck cancers on Sunday, June 4, 1 p.m., Building C, Level 1, Hall C4.

In recent years, Posner and colleagues at Dana-Farber have developed a multi-modality therapy for inoperable, locally advanced head and neck cancers that can reduce the need to remove critical organs while giving the patient good odds of survival. The first phase is induction chemotherapy with a combination of drugs followed by simultaneous fractionated radiation therapy and weekly treatment with carboplatin chemotherapy. Patients then have surgery if needed.

A combination of cisplatin and fluorouracil (5-FU) has been used for the induction chemotherapy. Posner's team has added docetaxel (Taxotere) as a third drug, and the clinical trial compared the three-drug versus the two-drug regimen. From 1999 to 2003, a total of 538 patients were randomized to the two treatments; 501 patients were evaluable. The patients were followed for at least two years, and 79 percent were followed for three years.

Survival estimates for three years showed that the addition of docetaxel reduced the r
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
4-Jun-2006

Page: 1 2
Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Lung cancer screening regimen provides opportunity for cure
3. Response to anti-HIV therapy improved if treatment begins six months after preventive regimen
4. Important factors in compliance with HIV regimens identified; and more
5. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
6. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
7. Dose-dense chemotherapy for early breast cancer found safe, similar to standard regimen
8. Lancet study: Pfizers Vfend equals two-drug candidemia regimen, with fewer serious side effects
9. Treatment regimen offers greater survival advantage for recurrent head and neck cancers
10. Steroid-free regimen with CellCept found comparable to standard therapy in liver transplantation
11. Breast cancer chemotherapy regimen associated with life-threatening complications